Abstract
Intermittent treatment withl-dopa over a 2-year period induced abnormal involuntary movements in MPTP-treated squirrel monkeys. Dyskinesias included a choreic and dystonic component. Dose-response curves for chorea and dystonia revealed that the same dose ofl-dopa (30 mg/kg) induced the highest score for both dyskinesias; however, the severity was much greater for chorea. Choreic movements were always most prevalent at the time of peak effect, whereas dystonia was apparent at the time of peak effect and at “end-of-dose”, and was occasionally observed spontaneously. Our findings indicate that squirrel monkeys treated with MPTP developl-dopa-induced dyskinesias which closely resemble those observed in Parkinson's disease. This species provides a valuable animal model to develop improved therapeutic agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barbeau A (1975) Diphasic dyskinesia during levodopa therapy. Lancet I:756
Bedard PJ, DiPaolo T, Falardeau P, Boucher R (1986) Chronic treatment withl-dopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]-Spiperone binding. Brain Res 379:294–299
Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR (1987) Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) J Neurol Sci 78:273–280
Cooper IS (1970) Clinical physiology of abnormal movements. In: Barbeau A, McDowell FH (eds)l-dopa and parkinsonism. FA Davis, Philadelphia, pp 170–179
Corsini GU, Onali PL, Masala C, Cianchetti C, Mangoni A, Gessa GL (1978) Apomorphine hydrochloride-induced improvement in Huntington's chorea. Arch Neurol 35:27–30
Criswell H, Mueller RA, Breese GR (1989) Priming of D1-dopamine receptor responses: long-lasting behavioural supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J Neurosci 9:125–133
Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrook MA (1987) MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 14:428–435
Duby SE, Cotzias GC, Papavasiliou PS, Lawrence WH (1972) Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol 27:474–480
Falardeau P, Bouchard S, Bedard PJ, Boucher R, DiPaolo T (1988) Behavioural and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 150:59–66
Gerlach J (1977) Relationship between tardive dyskinesia,l-dopainduced hyperkinesia and parkinsonism. Psychopharmacology 51:259–263
Graham WC, Crossman AR (1987) Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input. Eur J Pharmacol 142:479–481
Grandaz Perez FG, Jenner PG, Nomoto M, Stahl S, Quinn NP, Parkes JD, Critchley P, Marsden CD (1986) (+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease. Lancet I:906
Guy W (1976) Psychopharmacology Research Branch NIMH. Abnormal involuntary movement scale (AIMS). In: Guy W (ed) ECDEU Assessment manual for psychopharmacology, revised. DHEW, Rockville MD, pp 534–537
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442
Jenner P, Rose S, Boyce S, Kelly E, Kilpatrick G, Rupniak NMJ, Briggs R, Marsden CD (1986) Induction of parkinsonism in the common marmoset by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In: Fahn S. (ed) Recent developments in Parkinson's disease. Raven Press, New York, pp 137–146
Klawans HL, Weiner WJ (1974) Attempted use of haloperidol in the treatment ofl-dopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 37:427–430
Kovacic B, Domino EF (1982) A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD. J Clin Psychopharmacol 2:305–307
Lang AE (1985) Dopamine agonists in the treatment of dystonia. Clin Neuropharmacol 8:38–57
Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292:390–394
Lees AJ, Stern GM (1983) Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 44:1020–1023
Markham CH (1974) The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther 12:340–343
Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson's disease — clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworths, London, pp 96–122
Melamed E (1979) Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 36:308–310
Mones RJ, Elizan TS, Siegel GJ (1971) Analysis ofl-dopa induced dyskinesia in 61 patients with parkinsonism. J Neurol Neurosurg Psychiatry 34:668–673
Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 25:523–526
Muenter MD, Sharpless TS, Tyce GM, Darley FL (1977) Patterns of dystonia (“I-D-I” and “D-I-D”) in response tol-dopa therapy for Parkinson's disease. Mayo Clin Proc 52:163–174
Neale R, Gerhardt S, Fallon S, Liebman JM (1982) Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys. Psychopharmacology 77:223–228
Parent A, Smith Y (1987) Differental dopaminergic innervation of the two pallidal segments in the squirrel monkey(Saimiri sciureus). Brain Res 426:397–400
Protais P, Constentin J, Schwartz JC (1976) Climbing behaviour induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 60:1–6
Richfield EK, Young AB, Penney JB (1987) Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats and monkeys. J Comp Neurol 262:446–463
Robertson RG, Farmery SNM, Sambrook MA, Crossman AR (1989) Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res 476:317–322
Rupniak NMJ, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology 88:403–419
Rupniak NMJ, Tye SJ, Jenning CA, Loper AE, Bondi JV, Hichens M, Hand E, Iversen SD, Stahl SM (1989) Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 38:329–335
Smith Y, Lavoie B, Dumas J, Parent A (1989) Evidence for a distinct nigropallidal dopaminergic projection in the squirrel monkey. Brain Res 482:381–386
Stahl SM, Davis KL, Berger PA (1982) The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. J Clin Psychopharmacol 2:321–328
Stoessl AJ, Mak E, Calne DB (1985) (+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism. Lancet II:1330–1331
Tarsy D, Leopold N, Sax DS (1974) Physostigmine in choreiform movement disorders. Neurology 24:28–33
Tasker RR (1970) Significance and etiology of induced abnormal movements: physiological implications. In: Barbeau A, McDowell FH (eds)l-dopa and parkinsonism. FA Davis, Philadelphia, pp 159–163
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boyce, S., Rupniak, N.M.J., Steventon, M.J. et al. Characterisation of dyskinesias induced byl-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 102, 21–27 (1990). https://doi.org/10.1007/BF02245739
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245739